Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy
- 15 December 2007
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 46 (5) , 607-615
- https://doi.org/10.1097/qai.0b013e31815b7dba
Abstract
The extent to which the prognosis for AIDS and death of patients initiating highly active antiretroviral therapy (HAART) continues to be affected by their characteristics at the time of initiation (baseline) is unclear. We analyzed data on 20,379 treatment-naive HIV-1-infected adults who started HAART in 1 of 12 cohort studies in Europe and North America (61,798 person-years of follow-up, 1844 AIDS events, and 1005 deaths). Although baseline CD4 cell count became less prognostic with time, individuals with a baseline CD4 count 350 cells/μL (hazard ratio for AIDS = 2.3, 95% confidence interval [CI]: 1.0 to 2.3; mortality hazard ratio = 2.5, 95% CI: 1.2 to 5.5, 4 to 6 years after starting HAART). Rates of AIDS were persistently higher in individuals who had experienced an AIDS event before starting HAART. Individuals with presumed transmission by means of injection drug use experienced substantially higher rates of AIDS and death than other individuals throughout follow-up (AIDS hazard ratio = 1.6, 95% CI: 0.8 to 3.0; mortality hazard ratio = 3.5, 95% CI: 2.2 to 5.5, 4 to 6 years after starting HAART). Compared with other patient groups, injection drug users and patients with advanced immunodeficiency at baseline experience substantially increased rates of AIDS and death up to 6 years after starting HAART.Keywords
This publication has 33 references indexed in Scilit:
- Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesAIDS, 2007
- Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversionAIDS, 2006
- Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral TherapyClinical Infectious Diseases, 2005
- Factors Influencing Increases in CD4 Cell Counts of HIV?Positive Persons Receiving Long?Term Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2004
- Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapiesStatistics in Medicine, 2004
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSInternational Journal of Epidemiology, 2004
- Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapyStatistics in Medicine, 2004
- Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapyAIDS, 2003
- When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studiesAIDS, 2003
- Increase and Plateau of CD4 T-Cell Counts in the 3½ Years After Initiation of Potent Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001